An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
|Articles|October 5, 2021
Daily Medication Pearl: Ruxolitinib (Jakafi) for Myelofibrosis
Author(s)Saro Arakelians, PharmD
Ruxolitinib is indicated for intermediate or high-risk myelofibrosis, polycythemia vera, steroid-refractory acute graft-versus-host disease, and chronic graft-versus-host disease.
Advertisement
Medication Pearl of the Day: Ruxolitinib (Jakafi)
Ruxolitinib is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, steroid-refractory acute graft-versus-host disease, and chronic graft-versus-host disease.
Insight:
- Dosing:
- Myelofibrosis:
- The starting dose of ruxolitinib is based on patient’s baseline platelet count:
- Greater than 200 × 109 /L: 20 mg given orally twice daily.
- 100 × 109 /L to 200 × 109 /L: 15 mg given orally twice daily.
- 50 × 109 /L to less than 100 × 109 /L: 5 mg given orally twice daily.
- Polycythemia vera: The starting dose is 10 mg given orally twice daily.
- Acute graft-versus-host disease: starting dose is 5 mg given orally twice daily.
- Chronic graft-versus-host disease: starting dose is 10 mg given orally twice daily.
- The starting dose of ruxolitinib is based on patient’s baseline platelet count:
- Myelofibrosis:
- Dosage form: Tablets: 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg.
- Adverse events: The most common nonhematologic adverse events are bruising, dizziness, headache, and diarrhea.
- Mechanism of Action: Ruxolitinib inhibits Janus associated kinases (JAKs) JAK1 and JAK2, which mediate the signaling of several cytokines and growth factors that are important for hematopoiesis and immune function.
- Manufacturer: Incyte
Sources:
Advertisement
Related to this article
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5